BioNTech (ADR)

Biontech has lost massive market value since the COVID peak and is currently trading at around €80, about a quarter of its record high. Founders Uğur Şahin and Özlem Türeci are leaving the company to pursue new research projects, which further weighed on the share price. Biontech is now focusing on research into cancer vaccines and immunotherapies, but at the same time is shutting sites in Germany, risking loss of know‑how and staff despite large cash reserves. » More on t-online.de

BioNTech announced that by the expiration of the original deadline 184,071,410 CureVac shares (about 81.74% of the issued and outstanding shares) were validly tendered, thereby satisfying the minimum acceptance condition. All tendered shares were accepted; the post-offer period runs until Thursday, 18 December 2025, 6:01 a.m. CET, during which additional shareholders may tender. BioNTech will issue BioNTech ADSs or cash compensation payments for fractions to the tendering CureVac shareholders; non-tendering shareholders will also receive ADSs/cash compensation as part of the post-offer reorganization and their shares will subsequently no longer be tradable on a national exchange. Dutch withholding tax of 15% may generally apply to the BioNTech ADSs issued to non-tendering holders. » More on finanzen.net

After approval by the Federal Cartel Office, Biontech is launching a public exchange offer for all outstanding Curevac shares. Curevac shareholders can swap their securities for Biontech ADS, provisionally valued at about $5.46 per Curevac share; the final exchange value will be set five days before the offer ends on 3 December. The management board and supervisory board of Curevac recommend the swap, and major shareholders holding more than 57 percent have already agreed; a minimum acceptance threshold of 80 percent is required. » More on finanzen.net

BioNTech has launched a public exchange offer for all outstanding CureVac shares, converting each CureVac share into BioNTech-ADSs worth approximately $5.46. The exchange ratio will be determined by a VWAP-based adjustment mechanism; the offer is scheduled to run until December 3, 2025 (9:00 a.m. ET). The transaction is subject to conditions such as a minimum acceptance threshold of 80% (75% in certain circumstances) and regulatory approvals; BioNTech plans, upon closing, to fully acquire and restructure CureVac to strengthen its mRNA oncology pipeline. » More on finanzen.net

The Bundeskartellamt has approved Biontech's planned acquisition of Curevac and does not expect any restriction of innovation competition. Biontech intends to acquire Curevac through a share swap and says it plans to complete the deal by the end of the year. The authority stresses that Curevac currently has no approved marketed products and that the research pipelines of the two companies show little overlap, while Biontech already has market presence with Comirnaty. » More on n-tv.de